Navigation Links
Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
Date:2/10/2010

JERUSALEM, Israel, February 10 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that its Chief Scientific Officer, Miriam Kidron, Ph.D., was chosen to lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) to take place in Basel, Switzerland on February 11, 2010. Dr. Kidron will present the following abstract in Hall B at 3:15 pm: "Assessment of Oral Insulin Formulations in the Healthy Male Volunteers - Safety and Pharmacodynamic Comparisons".

Based on the conference website, the conference "presents professionals with cutting-edge technologies from entrepreneurs racing to develop effective and advanced devices and systems for the treatment and prevention of diabetes and related illnesses." For more information please visit the conference website at: http://www2.kenes.com/attd/pages/home.aspx.

Oramed is currently conducting a Phase 2B clinical trial in South Africa on its flagship product an oral insulin capsule. Results are expected at the end of the first quarter of 2010.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com.

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oramed, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and Oramed's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to Oramed's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of Oramed to differ materially from those expressed or implied in such forward looking statements. Oramed undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relations Contact:

    Oramed Pharmaceuticals Inc.
    Tara Horn
    USA: +1-646-240-4193
    Int'l: + 972-54-334-318
    Office: + 972-2-566-0001
    Email: tara@oramed.com


SOURCE Oramed Pharmaceuticals Inc.


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
2. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
3. Fibrocell Science, Inc. Names David Pernock Chief Executive Officer
4. Glycos Biotechnologies Appoints Chief Executive Officer
5. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
6. Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer
7. Dendreon Appoints Hans Bishop as Chief Operating Officer
8. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
9. Advanced Cell Technologys Chief Scientific Officer, Robert Lanza, Opening Plenary Speaker at the 3rd International Conference on Cell Therapy
10. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
11. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/25/2017)... ... February 25, 2017 , ... The ... in an ongoing effort to create meaningful change by increasing communication, partnerships ... with emphasis on consumers and patients’ mental health well-being. , Both organizations are ...
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  Aethlon Medical, ... following note authored by its Chairman and CEO, ... at the Munich Security Conference last Saturday, Bill ... virus could kill more people than nuclear weapons. Mr. ... U.S. and U.K. intelligence agencies, that scientific terrorists have ...
(Date:2/24/2017)... Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading ... financial results for the fourth quarter and fiscal year of ... Total sales in the fourth quarter of ... 13.6% in USD terms to $77.6 million from $68.3 million ... profit increased by 13.3% to $46.8 million from $41.3 million ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs ... to include an array of biochemical analyses critical for Lead Discovery. The ... hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, and ...
Breaking Biology Technology:
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
Breaking Biology News(10 mins):